We are live on
!
Find out more
GW
GW & Wade Portfolio holdings
AUM
$3.08B
1-Year Est. Return
18.99%
This Fund
S&P 500
This Quarter
Est. Return
+3.4%
1 Year Est. Return
+18.99%
3 Year Est. Return
+32.19%
5 Year Est. Return
+95.75%
10 Year Est. Return
+162.41%
AUM
$1.1B
AUM Growth
+$42.2M
(+4%)
Cap. Flow
+$12.2M
Cap. Flow
% of AUM
1.11%
Top 10 Holdings %
Top 10 Hldgs %
33.6%
Holding
243
New
14
Increased
122
Reduced
64
Closed
9
Top Buys
| 1 |
Pfizer
PFE
|
+$10.2M |
| 2 |
Medtronic
MDT
|
+$8.87M |
| 3 |
Southern Company
SO
|
+$5.12M |
| 4 |
iShares MSCI USA Min Vol Factor ETF
USMV
|
+$3.51M |
| 5 |
Walmart Inc
WMT
|
+$2.33M |
Top Sells
| 1 |
3M
MMM
|
+$10.3M |
| 2 |
Crown Castle
CCI
|
+$8.95M |
| 3 |
Amgen
AMGN
|
+$4.4M |
| 4 |
Vodafone
VOD
|
+$2.5M |
| 5 |
Travelers Companies
TRV
|
+$2.08M |
Sector Composition
| 1 | Technology | 11.55% |
| 2 | Industrials | 8.04% |
| 3 | Energy | 7.64% |
| 4 | Consumer Staples | 7.19% |
| 5 | Healthcare | 6.78% |
Similar funds
CC
PMEF
SS
GC
WMSA
WP
BWM
DI
GW & Wade's Q2 2019 Portfolio in Review
As of Q2 2019, GW & Wade held 243 positions worth $1.1B, up 4% from $1.06B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
GW & Wade's Q2 2019 filing shows 14 new, 122 increased, 64 reduced and 9 closed positions. Its largest new stake was GSK: 15,322 shares worth $767K. The largest sale was 3M, an estimated $10.3M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 12% a quarter earlier, followed by Industrials and Energy.
- GW & Wade's largest Q2 2019 buy was GSK: 15,322 shares worth $767K.
- GW & Wade added most to Pfizer in Q2 2019, an estimated $10.2M increase.
- GW & Wade's biggest Q2 2019 reduction was 3M, cutting an estimated $10.3M.
- GW & Wade fully exited Crown Castle in Q2 2019, selling an estimated $8.95M.
- GW & Wade's ten largest holdings make up 34% of its $1.1B portfolio in Q2 2019.
- GW & Wade opened 14 new positions and closed 9 in Q2 2019.
- GW & Wade's portfolio value rose 4% quarter-over-quarter to $1.1B.
Based on GW & Wade's 13F filing for Q2 2019, filed 12 Aug 2019.